{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:19Z","timestamp":1791478219779,"version":"4.3.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, meningococcal ACWY vaccine, MCV4, and menacwy. Articles from reference lists were included to identify potential relevant literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Data were limited to randomized phase II and III clinical studies published in the English language, evaluating the efficacy and safety of MenACWY-TT. Animal studies and studies not utilizing MenACWY-TT were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>One phase II and 4 phase III randomized clinical studies, enrolling approximately 7700 participants, aged 2 years to 97 years old found that MenACWY-TT was noninferior when compared to established MenACWY vaccines, as measured by surrogate immunogenicity end points. In studies evaluating primary dose vaccination, conducted in those aged 2 to 97 years of age, the difference in seroresponse rates, reported by the lower bound of the 95% CI, was (A) 1.1% to 14.8%, (C) 21% to 42.2%, (Y) 7.7% to 24.6%, and (W) 8.9% to 22.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Despite the low incidence of meningococcal disease in the United States, meningococcal disease causes significant morbidity and mortality if not prevented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MenACWY-TT is noninferior to currently approved quadrivalent meningococcal vaccines and shows similar immunogenicity and safety as both an initial vaccine for prevention as well as a booster dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211039873","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T01:27:03Z","timestamp":1630286823000},"page":"727-735","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["MenQuadfi (MenACWY-TT): A New Vaccine for Meningococcal Serogroups ACWY"],"prefix":"10.1177","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-2108","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"first","affiliation":[{"name":"University of Florida, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Galicia","sequence":"additional","affiliation":[{"name":"University of Florida, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-938X","authenticated-orcid":false,"given":"Eric F.","family":"Egelund","sequence":"additional","affiliation":[{"name":"University of Florida, Jacksonville, FL, USA"},{"name":"Infectious Disease Pharmacokinetics Laboratory, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,29]]},"reference":[{"key":"bibr1-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"bibr2-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/18.supplement_a.25"},{"key":"bibr3-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70251-6"},{"key":"bibr4-10600280211039873","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00321"},{"key":"bibr5-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"bibr6-10600280211039873","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909al"},{"key":"bibr7-10600280211039873","unstructured":"European Medicines Agency. Nimenrix. Accessed May 7, 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nimenrix"},{"key":"bibr8-10600280211039873","unstructured":"Sanofi. FDA approves MenQuadFi\u2122, the latest innovation in meningococcal (MenACWY) vaccination. Accessed April 24, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-04-24-07-00-00"},{"key":"bibr9-10600280211039873","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): ACIP live meeting archive\u2014June 2020. Accessed May 10, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/live-mtg-2020-6.html"},{"key":"bibr10-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.013"},{"key":"bibr11-10600280211039873","unstructured":"Menveo. Package insert. GlaxoSmithKline; 2020."},{"key":"bibr12-10600280211039873","unstructured":"Menactra. Package insert. Sanofi Pasteur Inc; 2018."},{"key":"bibr13-10600280211039873","unstructured":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants. ClinicalTrials.gov identifier: NCT04825223. Accessed May 5, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04825223"},{"key":"bibr14-10600280211039873","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521"},{"key":"bibr15-10600280211039873","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26109"},{"key":"bibr16-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"bibr17-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.067"},{"key":"bibr18-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"bibr19-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733867"},{"key":"bibr20-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733868"},{"key":"bibr21-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000261"},{"key":"bibr22-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733869"},{"key":"bibr23-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698"},{"key":"bibr24-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1902701"},{"key":"bibr25-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.034"},{"key":"bibr26-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.064"},{"key":"bibr27-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.045"},{"key":"bibr28-10600280211039873","unstructured":"Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in toddlers. ClinicalTrials.gov identifier: NCT02955797. Updated June 9, 2020. Accessed July 2, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02955797"},{"key":"bibr29-10600280211039873","unstructured":"United States Census Bureau. QuickFacts United States. Accessed July 2, 2021. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI425219"},{"key":"bibr30-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993"},{"key":"bibr31-10600280211039873","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease: surveillance. Accessed May 10, 2021. https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html"},{"key":"bibr32-10600280211039873","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.020"},{"key":"bibr33-10600280211039873","unstructured":"Food and Drug Administration. BLA clinical review memorandum. Accessed July 2, 2021. https:\/\/www.fda.gov\/media\/138120\/download"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211039873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211039873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211039873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:26Z","timestamp":1777374986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211039873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,29]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/10600280211039873"],"URL":"https:\/\/doi.org\/10.1177\/10600280211039873","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,29]]}}}